Aspira Women’s Health Names Torsten Hombeck as Chief Financial Officer
17 May 2023 - 6:05AM
Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a
bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced it has appointed Torsten Hombeck, Ph.D., as Chief
Financial Officer, replacing interim CFO Marlene McLennan. Dr.
Hombeck brings to Aspira extensive experience in the biotechnology
industry, finance, capital markets and M&A transactions, as
well as clinical and commercial product development and regulatory
filings. The change will be effective on June 15, 2023.
“We are pleased to welcome Torsten to the Aspira
management team as our new CFO,” said Nicole Sandford, President
and Chief Executive Officer of Aspira Women’s Health. “Torsten
brings a deep understanding of the capital markets, financial
strategy and business development from his over two decades of
senior level experience in the biotechnology industry, mostly with
publicly traded companies. We look forward to his guidance as he
helps to take us through to the next level of growth.”
Dr. Hombeck said, “I am excited to join Aspira at
this stage of its development. There is so much potential to
improve health outcomes for women, especially those facing the risk
of ovarian cancer. I look forward to playing a strategic role in
helping the company to achieve this mission. As a child of a cancer
survivor, this work holds a special place in my life.”
Dr. Hombeck joins Aspira from his role as CFO of
Akari Therapeutics (Nasdaq: AKTX) where he raised over $44 million
during his three year tenure there. His previous positions include
Chief Commercial and Strategy Officer and Managing Director at
Promethera Biosciences, and Co-Chief Executive Officer and Chief
Business Officer at Cytonet where he played an integral role in its
acquisition by Promethera. Dr. Hombeck also served as Chief
Financial Officer at both Agennix and GPC Biotech. He holds a
Masters in Business Administration and a Ph.D. in Finance.
Ms. Sandford continued, “We are grateful to Marlene
for her significant contributions to Aspira during a critical
transitional period. Under her leadership, we were able to make
progress on a number of our operational excellence goals.”
About Aspira Women’s Health Inc.Aspira
Women’s Health Inc. is transforming women’s gynecological health
with the discovery, development, and commercialization of
innovative testing options for women of all races and ethnicities,
starting with ovarian cancer.
Our ovarian cancer risk assessment portfolio is
marketed to healthcare providers as OvaSuiteSM. OvaWatchSM is
a non-invasive, blood-based test intended for use in the initial
clinical assessment of ovarian cancer risk in women with benign or
indeterminate adnexal masses for which surgical intervention may be
either premature or unnecessary. With a negative predictive value
(NPV) of 99%, OvaWatch allows physicians to confidently rule out
ovarian cancer malignancy and choose the appropriate clinical
management for the right patient at the right time.
Ova1Plus® combines our FDA-cleared products, Ova1® and
Overa®, to detect risk of ovarian malignancy in women with adnexal
masses planned for surgery.
EndoCheck™, Aspira’s first-of-its-kind non-invasive
diagnostic test for endometriosis, is currently in development.
Visit our website for more information
at www.aspirawh.com.
Forward-Looking StatementsThis
press release contains forward-looking statements, as defined in
the Private Securities Litigation Reform Act of 1995, including
statements regarding the planned launches of our serial monitoring
test and our EndoCheck diagnostic blood test by the end of 2023.
Forward-looking statements involve a number of risks and
uncertainties. Words such as “may,” “expects,” “intends,”
“anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,”
“should,” “continue,” “will,” “potential,” “projects” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions, including those described in the section entitled
“Risk Factors” in Aspira’s Annual Report on Form 10-K for the year
ended December 31, 2022, and in its Form 10-Q for the quarter ended
March 31, 2023. These risks include, but are not limited to: our
ability to continue as a going concern; our ability to comply with
Nasdaq’s continued listing requirements; impacts resulting from
potential changes to coverage of Ova1 through our Medicare
Administrative Carrier for Ova1; impacts resulting from or relating
to the COVID-19 pandemic and actions taken to contain it;
anticipated use of capital and its effects; our ability to increase
the volume of our product sales; failures by third-party payers to
reimburse for our products and services or changes to reimbursement
rates; our ability to continue developing existing technologies and
to develop, protect and promote our proprietary technologies; plans
to develop and perform laboratory developed tests; our ability to
comply with Food and Drug Administration (“FDA”) regulations that
relate to our products and to obtain any FDA clearance or approval
required to develop and commercialize medical devices; our ability
to develop and commercialize additional diagnostic products and
achieve market acceptance with respect to these products; our
ability to compete successfully; our ability to obtain any
regulatory approval required for our future diagnostic products; or
our suppliers’ ability to comply with FDA requirements for
production, marketing and post-market monitoring of our products;
our ability to maintain sufficient or acceptable supplies of
immunoassay kits from our suppliers; in the event that we succeed
in commercializing our products outside the United States, the
political, economic and other conditions affecting other countries;
changes in healthcare policy; our ability to comply with
environmental laws; our ability to comply with the additional laws
and regulations that apply to us in connection with the operation
of ASPiRA LABS; our ability to use our net operating loss
carryforwards; our ability to use intellectual property; our
ability to successfully defend our proprietary technology against
third parties; our ability to obtain licenses in the event a third
party successfully asserts proprietary rights; the liquidity and
trading volume of our common stock; material weaknesses in our
internal control over financial reporting; the concentration of
ownership of our common stock; our ability to retain key employees;
our ability to secure additional capital on acceptable terms to
execute our business plan; business interruptions; the
effectiveness and availability of our information systems; our
ability to integrate and achieve anticipated results from any
acquisitions or strategic alliances; future litigation against us,
including infringement of intellectual property and product
liability exposure; and additional costs that may be required to
make further improvements to our laboratory operations. The events
and circumstances reflected in Aspira’s forward-looking statements
may not be achieved or occur, and actual results could differ
materially from those projected in the forward-looking statements.
Aspira expressly disclaims any obligation to update, amend or
clarify any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by
law.
Investor Relations Contact:Monique
Kosse Managing DirectorLifeSci Advisors, LLCTel: 212-915-3820
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024